NCI Definition: Carcinoma that arises from the laryngeal epithelium. More than 90% of laryngeal carcinomas are squamous cell carcinomas. The remainder are adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas with neuroendocrine differentiation. 
Laryngeal carcinomas most frequently harbor alterations in TP53, CDKN2A, PIK3CA, KMT2D, and CCND1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KMT2D Mutation, and PIK3CA Mutation are the most common alterations in laryngeal carcinoma .
There are 3 clinical trials for laryngeal carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain laryngeal carcinoma as an inclusion criterion, 3 are phase 2 (3 open).
ERBB2 is the most frequent gene inclusion criterion for laryngeal carcinoma clinical trials .
Pembrolizumab, cetuximab, and demplatin pegraglumer are the most common interventions in laryngeal carcinoma clinical trials.
Significant Genes in Laryngeal Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.